Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR)
and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral
lentiginous melanoma treated with pembrolizumab